Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium catentulatum
- Development stage
- Unknown
- Lead developer
- University of Otago
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium catentulatum is an investigational oral live biotherapeutic product (probiotic) being developed by the University of Otago for the treatment of ulcerative colitis-related conditions, specifically pouchitis and elevated faecal calprotectin in patients with an ileal J pouch following surgery. The active ingredient consists of live Bifidobacterium catentulatum bacteria, administered in capsules containing 10^9 colony-forming units (CFU) twice daily for 8 weeks. Its mechanism of action involves the modulation of the gut microbiota to restore microbial balance (addressing dysbiosis) in the ileal pouch, which is intended to reduce intestinal inflammation as measured by faecal calprotectin levels. It is currently being evaluated in a double-blind, randomized, placebo-controlled Phase 1/2 clinical trial.
- Other names
- Bifidobacterium catentulatum
Beyond the preview
Go deeper on bifidobacterium catentulatum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium catentulatum.